Cancers (Jun 2022)

Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous Peoples

  • Mia Shepherdson,
  • Shalem Leemaqz,
  • Gurmeet Singh,
  • Courtney Ryder,
  • Shahid Ullah,
  • Karla Canuto,
  • Joanne P. Young,
  • Timothy J. Price,
  • Ross A. McKinnon,
  • Stephen J. Pandol,
  • Claire T. Roberts,
  • Savio George Barreto

DOI
https://doi.org/10.3390/cancers14122870
Journal volume & issue
Vol. 14, no. 12
p. 2870

Abstract

Read online

Background and Aims: A concerning rise in incidence of young-onset cancers globally led to the examination of trends in incidence and survival of gastrointestinal (GI) adenocarcinomas in the Northern Territory (NT), Australia, over a 28-year period, with a special emphasis on Indigenous peoples. Methods: This cross-sectional analysis of a prospective longitudinal database, NT Cancer Registry (1990–2017), includes all reported cases of GI (oesophagus, gastric, small intestinal, pancreas, colon, and rectum) adenocarcinomas. Poisson regression was used to estimate incidence ratio ratios, and survival was modelled using Cox proportional hazard models separately for people aged 18–50 years and >50 years. Results: A total of 1608 cases of GI adenocarcinoma were recorded during the time of the study. While the overall incidence in people 18–50 years remained unchanged over this time (p = 0.51), the rate in individuals aged >50 years decreased (IRR = 0.65 (95% CI 0.56–0.75; p 50 years (IRR = 0.67 95% CI 0.59–0.75; p p p p p 50 years IRR = 0.48 95% CI 0.40–0.57; p p 50 years HR = 1.66 95% CI 1.32–2.08; p < 0.0001). Conclusions: There is a trend towards an increased incidence of young-onset GI adenocarcinomas in the NT. Young Indigenous patients have lower incidence but worse survival across all GI subsites, highlighting significant health inequities in life expectancy. Targeted, culturally safe Indigenous community-focussed programs are needed for early detection and patient-centred management of GI adenocarcinomas.

Keywords